Please login to the form below
Shingrix
This page shows the latest Shingrix news and features for those working in and with pharma, biotech and healthcare.
GSK’s revenue drops by 18% in Q1 as performance pressures mount
Shingrix. Walmsley pinned GSK’s growth prospects on the launch of its HIV pill Cabenuva, as well as a potential RSV vaccine, currently in phase 3 trials, and a new ... GSK is confident that sales of Shingrix will increase in the second half of the year,
Latest news
-
Pfizer, Sanofi and others set to increase US drug prices in 2021
Pfizer and Sanofi are planning to keep almost all of their increase at 5% or lower, 3 Axis added, with GSK also increasing their prices of two vaccines, Shingrix and Pediarix,
-
GSK considers more divestments to help R&D push
Looking at the fourth quarter numbers, pharma sales slumped 5% to £4.6bn, but there was an encouraging 18% gain for vaccines to £1.74bn thanks to strong growth for Shingrix,
-
GSK boosts outlook thanks to strong respiratory and vaccine sales
Key Q3 drivers include Shingrix vaccine and asthma drug Nucala. GlaxoSmithKline has raised its profit forecast for the second consecutive quarter thanks to the strong sales of its shingles vaccine Shingrix ... Also bringing the forecast up is GSK’s
-
Shingrix lifts GSK in Q1, but two more vaccines are culled
The decision to drop the two vaccines came as another of GSK’s vaccines – Shingrix for shingles – saw its sales rocket in the first three months of the year, reaching £357m ( ... Shingrix’ performance helped GSK’s vaccine unit to a 23% sales
-
GSK upbeat on its return to oncology market
Nevertheless, there is expected to be strong performances from its Shingrix vaccine and next-generation respiratory drug Ellipta, which have both been the focus of GSK’s new drive towards commercial
Pfizer, Sanofi and others set to increase US drug prices in 2021
GSK considers more divestments to help R&D push
GSK upbeat on its return to oncology market
More from news
Approximately 9 fully matching, plus 21 partially matching documents found.
Latest Intelligence
-
Deal Watch January 2018
contain the adjuvant QS-21 Stimulon. In October 2017 GSK's QS-21 Stimulon herpes zoster vaccine, Shingrix, was approved by the FDA. GSK's malarial vaccine, Mosquirix which also contains
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- Client Services Director, Patient Engagement & Solutions, Lo...
-
Highly competitive salary
- Account Director, Publications, Opthalmology, Medical Communicat...
-
Highly competitive salary
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
-
Publications Director
-
Competitive Salary
- Senior Account Director, Publications, Women’s health, Medical C...
-
Highly competitive salary
-
Planner
-
Salary TBC
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Medical Writer, Rare diseases, Medical Communications age...
-
Highly competitive salary
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
- Group Account Director, Patient Engagement & Solutions, Lond...
-
Highly competitive salary
-
Senior Account Manager
-
Salary TBC
- Senior Account Director, Publications, Opthalmology, Medical Com...
-
Highly competitive salary
- Pfizer/BioNTech, AZ vaccines effective against Delta COVID-19 variant after two doses
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Novartis highlights potential of its radioligand therapy in prostate cancer at ASCO
- Positive late-stage results for Novartis’ radioligand therapy in advanced prostate cancer
- Court rules on AZ and EU’s COVID-19 vaccine dispute
- Disappointing results from CureVac’s COVID-19 vaccine as phase 2/3 study shows only 47% efficacy
- New data shows benefits for presymptomatic SMA patients treated with Zolgensma
- Stick or Twist? Healthcare brands in a (post) COVID-19 world
- Stick or twist? Looking at the patient experience as we emerge from the COVID pandemic
- Lockdown entertainment or healthcare revolution? The role of video games in healthcare
- GSK, Vir’s sotrovimab cuts hospitalisation and death risk by 79% in COVID-19 outpatients
- Tonix Pharmaceuticals to develop TNX-102 for long COVID syndrome
- Diversity and inclusion in clinical trials
- Pfizer/BioNTech, AZ vaccines effective against Delta COVID-19 variant after two doses
- J&J’s Darzalex shows ‘significant’ survival benefit in newly diagnosed multiple myeloma
- Oxford University, Prenetics to advance COVID-19 rapid testing for other infectious diseases
- Real-world data finds patients feel better on Entresto, says Novartis
- Pfizer takeover rumour ignites Amarin shares
PMHub
Madmicrobe Studios
MadMicrobe is an award-winning team of certified medical illustrators creating animations that draw audiences into a world of suspense, excitement,...
